#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14680	16S	1529	1529	99.93	16S.l15.c17.ctg.1	1941	743.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1684	1684	T	766	T,C	707,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14680	16S	1529	1529	99.93	16S.l15.c17.ctg.1	1941	743.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1418	1418	C	823	C,T,A,G	775,1,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26392	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3489	753.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1635	1635	A	904	A,G	838,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26392	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3489	753.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2269	2269	C	841	C	788	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26392	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3489	753.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2343	2343	A	859	A	823	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26392	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3489	753.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2895	2895	C	772	C,T	734,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2076	folP	855	855	100.0	folP.l15.c4.ctg.1	1501	137.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1018	1020	AGC	216;211;206	A;G;C	205;200;196	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5286	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3445	153.1	1	SNP	p	S91F	1	.	.	271	273	TTC	602	604	TTC	179;180;180	T;T;C	167;169;168	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5286	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3445	153.1	1	SNP	p	D95G	1	.	.	283	285	GGC	614	616	GGC	177;172;173	G;G;C,T	159;154;157,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5286	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3445	153.1	1	SNP	p	G95N	0	.	.	283	285	GGC	614	616	GGC	177;172;173	G;G;C,T	159;154;157,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1654	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1321	124.7	1	SNP	p	G45D	0	.	.	133	135	GGC	460	462	GGC	223;220;220	GGCGCGC,GGCGC;G;C	204,1;206;206	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	860	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	956	89.3	0	.	n	.	0	A197.	DEL	197	197	A	551	551	A	183	A	177	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4864	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2825	171.0	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1431	1433	GTC	195;196;195	G;T;C	181;181;180	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4864	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2825	171.0	1	SNP	p	D86N	0	.	.	256	258	GAC	537	539	GAC	186;186;185	G;A;C	174;171;174	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4864	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2825	171.0	1	SNP	p	R87I	0	.	.	259	261	CGT	540	542	CGT	182;183;187	C;G;T	172;173;173	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4864	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2825	171.0	1	SNP	p	S87R	1	.	.	259	261	CGT	540	542	CGT	182;183;187	C;G;T	172;173;173	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4864	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2825	171.0	1	SNP	p	R87W	0	.	.	259	261	CGT	540	542	CGT	182;183;187	C;G;T	172;173;173	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4864	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2825	171.0	1	SNP	p	S88P	0	.	.	262	264	TCC	543	545	TCC	187;187;187	T;C;C	176;175;178	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4274	parE	1986	1986	99.9	parE.l15.c17.ctg.1	2571	165.4	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1269	1271	TGC	179;178;177	T,C;G;C	163,2;164;165	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4274	parE	1986	1986	99.9	parE.l15.c17.ctg.1	2571	165.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1479	1481	GGC	212;208;210	G;G;C,T,G	197;192;192,1,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4074	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2453	165.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1357	1359	GCA	246;245;244	G;C,T;A	228;223,1;231	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4074	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2453	165.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1360	1362	ATC	248;248;249	A;T;C	234;235;234	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4074	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2453	165.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1372	1374	GTG	250;248;250	G;T;G	234;231;229	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4074	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2453	165.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1372	1374	GTG	250;248;250	G;T;G	234;231;229	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4074	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2453	165.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1876	1878	ACC	204;204;202	A;C;C	187;195;193	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4074	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2453	165.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1930	1932	GCG	179;181;180	G;C,G;G	159;139,1;151	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4074	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2453	165.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1930	1932	GCG	179;181;180	G;C,G;G	159;139,1;151	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4074	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2453	165.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2053	2055	GGC	192;186;187	G;G;C	178;171;173	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4074	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2453	165.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2062	2064	GGC	189;189;189	G;G;C	174;172;172	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4074	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2453	165.4	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2080	2082	TCG	187;187;187	T,G;C,T;G,C	137,6;149,1;149,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5664	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	2957	190.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1522	1524	CCG	222;222;219	C;C;G	196;203;195	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2320	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1811	127.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	581	581	C	152	C	139	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2972	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1379	211.1	0	.	p	.	0	N38E	NONSYN	112	114	AAT	304	306	GAA	269;267;266	G;A;A	252;251;250	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2972	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1379	211.1	0	.	p	.	0	N134D	NONSYN	400	402	AAT	592	594	GAT	231;232;229	G;A;T	215;219;217	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2972	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1379	211.1	0	.	p	.	0	P175S	NONSYN	523	525	CCA	715	717	TCA	245;246;249	T;C;A	224;228;228	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2972	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1379	211.1	0	.	p	.	0	A218V	NONSYN	652	654	GCC	844	846	GTC	260;257;257	G;T;C	245;239;243	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2972	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1379	211.1	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1174	1176	GCA	225;226;224	G;C,A;A	214;216,1;211	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2972	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1379	211.1	1	SNP	p	G120K	1	.	.	358	360	AAG	550	552	AAG	235;235;235	A;A;G	218;217;218	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2972	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1379	211.1	1	SNP	p	A121D	1	.	.	361	363	GAC	553	555	GAC	229;226;227	G,C;A;C	210,1;208;211	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2972	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1379	211.1	1	SNP	p	D121N	0	.	.	361	363	GAC	553	555	GAC	229;226;227	G,C;A;C	210,1;208;211	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10460	rpoB	4179	4179	100.0	rpoB.l6.c30.ctg.1	4885	213.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2084	2086	AAT	207;206;206	A;A;T	190;189;187	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1068	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1000	106.2	1	SNP	p	V57M	1	.	.	169	171	ATG	488	490	ATG	216;216;214	A;T;G	206;205;203	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
